Perioperative and postoperative use of immunosuppressive agents in liver transplantation

International Anesthesiology Clinics

Volumn 44, Issue 3, 2006, Pages 51-68

  Krok, Karen L ^a   Thuluvath, Paul J ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; CALCINEURIN;

ARTHRALGIA; ASEPTIC NECROSIS; BONE MARROW SUPPRESSION; CANCER; CARDIOMEGALY; CATARACT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG INDUCED HEADACHE; EDEMA; GINGIVA HYPERPLASIA; HEMOLYTIC UREMIC SYNDROME; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOMAGNESEMIA; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MOUTH ULCER; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PEPTIC ULCER; PERSONALITY DISORDER; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; TREMOR; VEIN THROMBOSIS; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT; DRUG ANTAGONISM; DRUG INTERACTION; GRAFT REJECTION; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD;

CALCINEURIN; DRUG INTERACTIONS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PERIOPERATIVE CARE; POSTOPERATIVE PERIOD;

EID: 33747515291     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aia.0000210803.45383.35     Document Type: Review

References (48)

1. Vilatoba M, Contreras JL, Eckhoff DE. New immunosuppressive strategies in liver transplantation: balancing efficacy and toxicity. Curr Opin Organ Transplant. 2003;8:139-145.
2. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638-645.
3. Adams DH, Neuberger JM. Treatment of acute rejection. Semin Liver Dis. 1992;12:80-88.
4. Neuberger J, Adams DH. What is the significance of acute liver allograft rejection? J Hepatol. 1998;29:143-150.
5. Pfeilschifter J, Muhl H. Immunopharmacology: anti-inflammatory therapy targeting transcription factors. Eur J Pharmacol. 1999;375:237-245.
6. Mueller XM. Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants. Ann Thorac Surg. 2004;77:354-362.
7. Fisher NC, Nightingale PG, Gunson BK, et al. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation. 1998;66:59-66.
8. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-940.
9. Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int. 1996;50:1089-1100.
10. Neuhaus P, Blumhardt G, Bechstein WO, et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. Transplantation. 1995;59:31-40.
11. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994;344:423-428.
12. McDiarmid SV, Busuttil RW, Ascher NL, et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. Transplantation. 1995;59:530-536.
13. O'Grady JG, Burroughs A, Hardy P, et al. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360:1119-1125.
14. Gonzalez-Pinto IM, Rimola A, Margarit C, et al. Five-year follow-up of a trial comparing tacrolimus and cyclosporine microemulsion in liver transplantation. Transplant Proc. 2005;37:1713-1715.
15. Kahan BD. The limitations of calcineurin and mTOR inhibitors: new directions for immunosuppressive strategies. Transplant Proc. 2002;34:130-133.
16. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081-1085.
17. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51:278-298.
18. Granger DK. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc. 2001;33:3241-3244.
19. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl. 2001;7:442-450.
20. Sterneck M, Fischer L, Gahlemann C, et al. Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial. Ann Transplant. 2000;5:43-46.
21. Levy GA, Grant D, Paradis K, et al. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation. 2001;71:160-163.
22. Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc. 2003;35:209S-216S.
23. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67:1036-1042.
24. Trotter JF. Sirolimus in liver transplantation. Transplant Proc. 2003;35:193S-200S.
25. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996;51:865-894.
26. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transplant. 2002;8:132-142.
27. Petz W, Spada M, Bertani A, et al. Experience with the use of basiliximab in liver transplantation - use in pediatric and adult recipients in combination with cyclosporine or tacrolimus. Transplant Proc. 2002;34:1966-1967.
28. Carswell CI, Plosker GL, Wagstaff AJ. Daclizumab: a review of its use in the management of organ transplantation. BioDrugs. 2001;15:745-773.
29. Niemeyer G, Koch M, Light S, et al. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant. 2002;2:454-460.
30. Hirose R, Roberts JP, Quan D, et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation. 2000;69:307-311.
31. Eckhoff DE, McGuire B, Sellers M, et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation. 2000;69:1867-1872.
32. Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation. 2004;77:1209-1214.
33. Chong AS, Huang W, Liu W, et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation. 1999;68:100-109.
34. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation. 2002;73:358-366.
35. Bilolo KK, Ouyang J,Wang X, et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. Transplantation. 2003;75:1881-1887.
36. Suzuki S. FTY720: mechanisms of action and its effect on organ transplantation (review). Transplant Proc. 1999;31:2779-2782.
37. Brinkmann V, Pinschewer DD, Feng L, et al. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation. 2001;72:764-769.
38. Schuurman HJ, Menninger K, Audet M, et al. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD. Transplantation. 2002;74:951-960.
39. Tamura A, Li XK, Funeshima N, et al. Immunosuppressive therapy using FTY720 combined with tacrolimus in rat liver transplantation. Surgery. 2000;127:47-54.
40. Helderman JH, Bennett WM, Cibrik DM, et al. Immunosuppression: practice and trends. Am J Transplant. 2003;3:41-52.
41. Kamar N, Ribes D, Sandres-Saune K, et al. Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C. Transplant Proc. 2004;36:2757-2761.
42. Kamar N, Borde JS, Sandres-Saune K, et al. Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C. Clin Transplant. 2005;19:83-89.
43. Eason JD, Loss GE, Blazek J, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transplant. 2001;7:693-697.
44. Tector AJ, Fridell JA, Mangus RS, et al. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transplant. 2004;10:404-407.
45. Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation. 2003;75:1396-1399.
46. Boillot O, Mayer DA, Boudjema K, et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transplant. 2005;11:61-67.
47. Sellers MT, McGuire BM, Haustein SV, et al. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis. Transplantation. 2004;78:1212-1217.
48. Gruttadauria S, Vasta F, Mandala L, et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant Proc. 2005;37:2611-2613.